Christina Neal
Medical · Waldorf, MDNPI 1750320990
Payments from drug & device makers
Across 193 payments — averaging $19.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Lilly USA, LLC$594
- AbbVie$569
- Exact Sciences$279
- AstraZeneca$204
- Pfizer$160
- plus $984 from 23 others
What the payments were for
- Food & beverage$3,821100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 52 | $1,031 |
| Lilly USA, LLC | 32 | $594 |
| AbbVie | 31 | $569 |
| Exact Sciences | 11 | $279 |
| AstraZeneca | 12 | $204 |
| Pfizer | 7 | $160 |
| Boehringer Ingelheim | 5 | $121 |
| Sanofi-aventis U.S. LLC | 4 | $102 |
| GSK | 5 | $85 |
| Vanda Pharmaceuticals Inc. | 3 | $74 |
| Shield Therapeutics Inc | 3 | $67 |
| Astellas Pharma US Inc | 3 | $66 |
| Abbott | 2 | $51 |
| Evofem Biosciences, Inc. | 2 | $40 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $39 |
| Seqirus USA Inc | 2 | $36 |
| Boston Scientific | 2 | $35 |
| Mayne Pharma Commercial LLC | 1 | $34 |
| Ironwood Pharmaceuticals, Inc | 2 | $29 |
| Endo Pharmaceuticals Inc. | 2 | $29 |
| Corcept Therapeutics | 1 | $29 |
| Currax Pharmaceuticals LLC | 2 | $24 |
| Xeris Pharmaceuticals, Inc. | 1 | $21 |
| Phathom Pharmaceuticals, Inc. | 1 | $21 |
| Phadia US Inc. | 1 | $18 |
| Amgen | 1 | $18 |
| Viiv Healthcare Company | 1 | $15 |
| Merck | 1 | $15 |
| Kaleo, Inc. | 1 | $14 |
How this compares
$3,821 in reported general payments places this provider in the 80th percentile of 543 medical providers in Maryland.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 39 | $66,444 |
| MounjaroTirzepatide | 21 | $27,992 |
| EliquisApixaban | 11 | $6,410 |
| Olmesartan Medoxomil | 41 | $2,027 |
| Rosuvastatin Calcium | 70 | $1,367 |
| Valsartan | 27 | $1,349 |
| Atorvastatin Calcium | 91 | $958 |
| Estradiol | 12 | $914 |
| ValacyclovirValacyclovir Hcl | 12 | $717 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 23 | $537 |
| NitrofurantoinNitrofurantoin Macrocrystal | 17 | $522 |
| Simvastatin | 27 | $496 |
| Levothyroxine Sodium | 38 | $473 |
| Escitalopram Oxalate | 34 | $382 |
| Omeprazole | 26 | $360 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,031 | $66,44439 claims |
| Lilly USA, LLCMounjaro | $594 | $27,99221 claims |
| PfizerEliquis | $160 | $6,41011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 543 medical providers in Maryland.
Other medical in Waldorf
- Monica LeidWaldorf$8K
- Victoria TrottStevensville$94K
- Sarah SagorskyBaltimore$68K
- Emily GrisnikLeonardtown$62K
- Jennifer HamiltonBel Air$52K
- Kristina TrunnellFrederick$51K
- Karen ScottAnnapolis$49K
- Nicholas WunderAberdeen$40K
- Sarah JamiesonFrederick$34K
- Jayme WilliamsCatonsville$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.